Another twist in Cardiff’s onvansertib plan
Front-line phase 3 plans take shape, as the company claims a new success, this time in pancreatic cancer.
Bridge mirrors Black Diamond and Blueprint’s search for something better
The companies have all switched to improved fourth-generation EGFR projects in lung cancer, a fact that likely shows how competitive this field has become.
Approval milestones – Hutchmed, SpringWorks, Crispr and Ionis eye firsts
A work-stretched US FDA has several key approval application still to review by the end of 2023.
